Cornerstone Pharmaceuticals' CPI-613 Phase I Hematologic Malignancies Trial Data Published in AACR's Clinical Cancer Research
October 07, 2014 08:45 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 7, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from the Phase I...
Cornerstone Pharmaceuticals Clinical Data on CPI-613 to be Presented at ASCO 2014
May 14, 2014 17:00 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., May 14, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from a Phase I...
Cornerstone Pharmaceuticals Lead Compound CPI-613 Demonstrates Ability to Disrupt Growth of Cancer Cells
March 12, 2014 16:25 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., March 12, 2014 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that its first-in-class...
Cornerstone Pharmaceuticals Presents Updated Phase I Data for CPI-613 at 2013 American Society of Hematology Annual Meeting
December 09, 2013 17:15 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced updated results from a Phase...
Cornerstone Pharmaceuticals to Present on Cancer Metabolism at Target TME 2013 Workshop
November 13, 2013 08:08 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 13, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, announced today its Vice President of...
Cornerstone Pharmaceuticals to Present CPI-613 Phase I Results at 2013 American Society of Hematology Annual Meeting
November 11, 2013 08:08 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 11, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from a Phase I...
Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 in Patients With Locally Advanced or Metastatic Pancreatic Cancer
October 31, 2013 08:08 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell Lung Cancer
October 24, 2013 08:08 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 24, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot...
Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for Treatment of Myelodysplastic Syndrome
October 03, 2013 08:08 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 3, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the U.S. Food and Drug...
Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613 for the Treatment of Myelodysplastic Syndrome
September 25, 2013 08:08 ET
|
Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., Sept. 25, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today...